Silenor Deal Gives P&G Easy Access To Rx Market, Possible OTC Sales
Procter & Gamble's license to market the insomnia drug Silenor lets the firm re-enter the Rx drug market without development costs and opens the door to a potential OTC switch
Procter & Gamble's license to market the insomnia drug Silenor lets the firm re-enter the Rx drug market without development costs and opens the door to a potential OTC switch